8 December 2021 - The high price tag of new anticancer drugs has fuelled debate about the value of these treatments, given the marginal clinical benefit of some newly approved treatments. 

But that debate is complicated by a lack of consensus around the definition of value and the different views of stakeholders in cancer care.

Read Regulatory Affairs Professional Society article